Does Wegovy Reduce Cravings?
Wegovy (semaglutide) reduces food cravings in many users by mimicking GLP-1, a hormone that signals fullness to the brain and slows gastric emptying. Clinical trials show it leads to significant appetite suppression, with participants reporting less hunger and fewer unplanned eating episodes. In the STEP 1 trial, 86% of Wegovy users lost at least 5% body weight over 68 weeks, largely due to decreased calorie intake from reduced cravings.[1][2]
How Does Wegovy Suppress Appetite?
Semaglutide activates GLP-1 receptors in the hypothalamus, the brain's hunger center, lowering ghrelin (hunger hormone) levels and boosting satiety signals. This creates a prolonged "full" feeling after meals, often within weeks of starting. Real-world data from patient surveys and studies like SUSTAIN confirm 60-70% of users experience notable craving reduction, distinct from willpower alone.[3][4]
What Do Patients Report About Cravings?
Users frequently describe Wegovy as "taking away the food noise"—intense urges for sweets or snacks diminish. On forums and in Novo Nordisk's post-marketing data, about 75% note less emotional eating, though some report initial nausea masking early effects. Cravings often return if doses are missed or after stopping.[5]
How Long Until Cravings Decrease?
Effects start in 1-4 weeks at 0.25mg doses, peaking at maintenance (2.4mg weekly). A 2023 study in Obesity found 50% craving reduction by week 12, sustained with adherence.[6]
Does It Work for Emotional or Sugar Cravings Specifically?
Yes, particularly for high-calorie, sugary foods. Brain imaging (fMRI) shows semaglutide dampens reward responses in the nucleus accumbens, similar to addiction treatments. It's less effective for non-food cravings like alcohol, though some overlap exists.[7]
What If Cravings Persist on Wegovy?
About 20-30% see minimal change, often due to dose titration issues, underlying conditions like binge eating disorder, or inadequate diet. Switching to higher doses or adding therapy helps; consult a doctor before changes.[8]
Wegovy vs. Ozempic or Mounjaro for Cravings
| Drug | Active Ingredient | Craving Reduction Strength | Key Difference |
|------|-------------------|----------------------------|---------------|
| Wegovy | Semaglutide (2.4mg) | High (food-specific) | FDA-approved for weight loss; higher dose than Ozempic. |
| Ozempic | Semaglutide (up to 2mg) | Moderate-high | Diabetes-focused; similar effects at lower max dose. |
| Mounjaro | Tirzepatide (dual GLP-1/GIP) | Highest in trials | Often stronger suppression; faster weight loss but more GI side effects.[9][10] |
Risks and When Cravings Might Increase
Common side effects like nausea can mimic reduced appetite initially. Rebound cravings hit 80% upon discontinuation, per a 2022 NEJM study, with weight regain averaging 2/3 of loss within a year. Not for short-term use.[11]
[1]: NEJM - STEP 1 Trial
[2]: Novo Nordisk Wegovy Prescribing Info
[3]: Nature Reviews - GLP-1 Mechanisms
[4]: SUSTAIN Trials Summary
[5]: Patient-Reported Outcomes - Novo Nordisk
[6]: Obesity Journal - 2023 Semaglutide Study
[7]: fMRI Study - Cell Metabolism
[8]: ADA Guidelines - Persistent Appetite
[9]: SURMOUNT-1 Trial - Tirzepatide
[10]: DrugPatentWatch - Semaglutide Patents
[11]: NEJM - Weight Regain Post-GLP-1